Evidence map›Paper›PMID 37014138›Full record

ArticleAmerican journal of respiratory cell and molecular biology2023

Enhanced Lyn Activity Causes Severe, Progressive Emphysema and Lung Cancer.

Evelyn Tsantikos, Timothy A Gottschalk, Elan L'Estrange-Stranieri, Caitlin A O'Brien, April L Raftery, Lakshanie C Wickramasinghe, Jonathan L McQualter, Gary P Anderson, Margaret L Hibbs

Abstract read
PubMed Publisher
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Evelyn TsantikosLeukocyte Signalling Laboratory, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.
Timothy A GottschalkLeukocyte Signalling Laboratory, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.
Elan L'Estrange-StranieriLeukocyte Signalling Laboratory, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.
Caitlin A O'BrienLeukocyte Signalling Laboratory, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.
April L RafteryLeukocyte Signalling Laboratory, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.
Lakshanie C WickramasingheLeukocyte Signalling Laboratory, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.
Jonathan L McQualterSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology (RMIT) University, Melbourne, Victoria, Australia; and.
Gary P AndersonLung Health Research Centre, Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0001-6580-3398
Margaret L HibbsLeukocyte Signalling Laboratory, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0002-3751-6751
Monash University · AURMIT University · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidemiological patterns of incident chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma are changing, with an increasing fraction of disease occurring in patients who are never-smokers or were not exposed to traditional risk factors. However, causative mechanism(s) are obscure. Overactivity of Src family kinases (SFKs) and myeloid cell-dependent inflammatory lung epithelial and endothelial damage are independent candidate mechanisms, but their pathogenic convergence has not been demonstrated. Here we present a novel preclinical model in which an activating mutation in Lyn, a nonreceptor SFK that is expressed in immune cells, epithelium, and endothelium-all strongly implicated in the pathogenesis of COPD-causes spontaneous inflammation, early-onset progressive emphysema, and lung adenocarcinoma. Surprisingly, even though activated macrophages, elastolytic enzymes, and proinflammatory cytokines were prominent, bone marrow chimeras formally demonstrated that myeloid cells were not disease initiators. Rather, lung disease arose from aberrant epithelial cell proliferation and differentiation, microvascular lesions within an activated endothelial microcirculation, and amplified EGFR (epidermal growth factor receptor) expression. In human bioinformatics analyses,

Indexed as

Adenocarcinoma of LungEmphysemaLung NeoplasmsPulmonary Disease, Chronic ObstructivePulmonary EmphysemaErbB ReceptorsHumanssrc-Family KinasesErbB Receptorslyn protein-tyrosine kinasesrc-Family Kinasesactivating mutationadenocarcinomachronic obstructive pulmonary diseaseemphysemaimpaired lung function

Identifiers

PMID37014138
OpenAlexW4362521276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.